Trial Profile
ASP1941 Phase II Clinical Study - A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 28 Jun 2010 Results have been presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) according to an Astellas media release.
- 25 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 18 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.